OBJECTIVE: To report all pregnancies to date after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for the conservative treatment of clinically significant uterine fibroids. DESIGN: Prospective registry of all known pregnancies occurring after MRgFUS maintained by the device manufacturer and reported to the Food and Drug Administration. SETTING: World experience of pregnancies after treatment with reports from 13 sites in seven countries. PATIENT(S): Fifty-one reproductive-age women with uterine leiomyomas. INTERVENTION(S): Women underwent MRgFUS treatment for symptomatic uterine leiomyomas before this report. MAIN OUTCOME MEASURE(S): Pregnancy outcomes and complications. RESULT(S): Fifty-four pregnancies in 51 women have occurred after MRgFUS treatment of uterine leiomyomas. The mean time to conception was 8 months after treatment. Live births occurred in 41% of pregnancies, with a 28% spontaneous abortion rate, an 11% rate of elective pregnancy termination, and 11 (20%) ongoing pregnancies beyond 20 gestational weeks. The mean birth weight was 3.3 kg, and the vaginal delivery rate was 64%. CONCLUSION(S): Preliminary pregnancy experience after MRgFUS is encouraging, with a high rate of delivered and ongoing pregnancies. Copyright 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
OBJECTIVE: To report all pregnancies to date after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for the conservative treatment of clinically significant uterine fibroids. DESIGN: Prospective registry of all known pregnancies occurring after MRgFUS maintained by the device manufacturer and reported to the Food and Drug Administration. SETTING: World experience of pregnancies after treatment with reports from 13 sites in seven countries. PATIENT(S): Fifty-one reproductive-age women with uterine leiomyomas. INTERVENTION(S): Women underwent MRgFUS treatment for symptomatic uterine leiomyomas before this report. MAIN OUTCOME MEASURE(S): Pregnancy outcomes and complications. RESULT(S): Fifty-four pregnancies in 51 women have occurred after MRgFUS treatment of uterine leiomyomas. The mean time to conception was 8 months after treatment. Live births occurred in 41% of pregnancies, with a 28% spontaneous abortion rate, an 11% rate of elective pregnancy termination, and 11 (20%) ongoing pregnancies beyond 20 gestational weeks. The mean birth weight was 3.3 kg, and the vaginal delivery rate was 64%. CONCLUSION(S): Preliminary pregnancy experience after MRgFUS is encouraging, with a high rate of delivered and ongoing pregnancies. Copyright 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
Authors: Fabiana Ferrari; Francesco Arrigoni; Anna Miccoli; Sara Mascaretti; Eva Fascetti; Giulio Mascaretti; Antonio Barile; Carlo Masciocchi Journal: Radiol Med Date: 2015-09-09 Impact factor: 3.469
Authors: James H Segars; Estella C Parrott; Joan D Nagel; Xiaoxiao Catherine Guo; Xiaohua Gao; Linda S Birnbaum; Vivian W Pinn; Darlene Dixon Journal: Hum Reprod Update Date: 2014-01-08 Impact factor: 15.610
Authors: Jamie N Bakkum-Gamez; Shannon K Laughlin; Jani R Jensen; Clement O Akogyeram; Sandhya Pruthi Journal: Mayo Clin Proc Date: 2011-02-09 Impact factor: 7.616
Authors: Carlo Masciocchi; Francesco Arrigoni; Fabiana Ferrari; Aldo Victor Giordano; Sonia Iafrate; Ilaria Capretti; Ester Cannizzaro; Alfonso Reginelli; Anna Maria Ierardi; Chiara Floridi; Alessio Salvatore Angileri; Luca Brunese; Antonio Barile Journal: Med Oncol Date: 2017-02-24 Impact factor: 3.064